Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Raptor Pharmaceuticals reports phase III results on RP-103

July 26, 2011

Bionovo completes animal toxicology studies of Menerba

July 26, 2011

Array BioPharma patents new CSF-1-R inhibitors

July 26, 2011

CHMP makes recommendations following review of pioglitazone-containing medicines

July 25, 2011

Potent PTP-1B-targeted antisense therapy enters phase I trial in type 2 diabetes

July 25, 2011

Mochida Pharmaceutical prepares new free fatty acid FFA1 receptor agonists

July 25, 2011

Manhattan Pharmaceuticals and FDA reach agreement on SPA for phase III AST-726 trial

July 22, 2011

Galapagos small-molecule SARM enters proof-of-mechanism phase I trial

July 20, 2011

FDA committee issues opinion on approval of dapagliflozin for type 2 diabetes

July 20, 2011

New estrogen-related receptor-alpha inverse agonists reported

July 20, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...